Interferon Therapy for Malignant Solid Tumors

Title: Interferon Therapy for Malignant Solid Tumors

Volume: 5 Issue: 2

Author(s): Katherine E. Warren and Howard A. Young

Affiliation:

Keywords: Interferon, PEG-Intron, cytokine, cancer, malignancy, tumor, anti-tumor drugs

Abstract: It has been over 50 years since the discovery of interferon. While initially touted as “the wonder drug” for cancer therapy, the reality of interferon use as a treatment for cancer has been far different. Today, interferon is used predominantly as adjuvant therapy in renal cell carcinoma and melanoma and is being evaluated for potential new applications in other malignancies, including leukemias, lymphomas, ovarian and prostate cancer, and tumors of the central nervous system. In this review we will discuss the outcome and challenges of interferon administration in malignancies and the future of this first “cytokine” in cancer therapy.

Cite this article as:

E. Warren Katherine and A. Young Howard, Interferon Therapy for Malignant Solid Tumors, Current Drug Therapy 2010; 5 (2) . https://dx.doi.org/10.2174/157488510791065058